Previous 10 | Next 10 |
home / stock / glpg / glpg articles
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current f...
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 C...
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the successful completion of the tra...
On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: ...
Strategic collaboration and licensing agreement further strengthens Galapagos' growing early-stage pipeline in oncology precision medicine C...
Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos' Chief Commerci...
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the first patient has been dos...
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational i...
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will host a Key Opinion Lead...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...
2024-05-11 10:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...